Close Menu

NEW YORK – Revolution Medicines on Saturday presented data on the preliminary activity of RMC-4630 in combination with cobimetinib (Genentech/Exelixis' Cotellic) in KRAS-mutated colorectal cancer, and said that it will study its SHP2 inhibitor in combination with a drug being advanced by AstraZeneca.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.